Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer

Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer

285322

Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer

Sutro Biopharma‘s Phase 1 clinical trial has begun testing the recommended dose of STRO-002 in heavily pretreated patients with advanced ovarian cancer. “We are excited to be part of the STRO-002-GM1 dose-expansion study and to provide additional clinical data to show the potential of this therapeutic for ovarian patients with limited treatment options,” Lainie Martin, MD, trial investigator and leader of the gynecology/oncology program at the Hospital of the University of Pennsylvania, said in a press…

You must be logged in to read/download the full post.